cryoglobulinemia: Cryoglobulinemia is a type of vasculitis that is caused by abnormal proteins (antibodies) in the blood called 'cryoglobulins.' At cold temperatures, these proteins become solid or gel-like, which can block blood vessels and cause a variety of health problems. Many people affected by this condition will not experience any unusual signs or symptoms. When present, symptoms vary but may include breathing problems; fatigue; glomerulonephritis ; joint or muscle pain; purpura ; Raynaud's phenomenon ; skin death; and/or skin ulcers. In some cases, the exact underlying cause is unknown; however, cryoglobulinemia can be associated with a variety of conditions including certain types of infection; chronic inflammatory diseases (such as autoimmune disease ); and/or cancers of the blood or immune system . Treatment varies based on the severity of the condition, the symptoms present in each person and the underlying cause.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
56 |
4. Check minimum number of eventsNone |
56 |
5. Include endpointsNone |
56 |
6. Filter based on genotype QC (FinnGen only) |
56 |
Control definitions (FinnGen only)
- Control exclude
- D3_IMMUNEMECHANISM
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D89
- Name in latin
- Cryoglobulinaemia
Similar endpoints
↥List of similar endpoints to
Cryoglobulinemia
based on the number of shared cases.
Similar with more cases:
- Other disorders involving the immune mechanism, not elsewhere classified
- Certain disorders involving the immune mechanism
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 308 | 146 | 161 |
| Only index persons | 253 | 121 | 132 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.00 | 0.00 | 0.00 |
| Only index persons | 0.00 | 0.00 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 58.79 | 59.34 | 58.14 |
| Only index persons | 56.02 | 55.87 | 56.15 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 56 | 25 | 31 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 55.57 | 50.01 | 60.05 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
No data available
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
16
11
19.96
18.37
3.2
1.4
0.2
0.3
g/l
0.47
16
11
16
12
18.27
17.54
3.1
1.4
1.2
1.2
g/l
0.09
16
12
13
10
16.63
13.85
1.4
1.4
—
—
—
0
0
43
146
9.38
13.85
10.3
3.0
—
—
—
0
0
48
186
12.01
13.81
28.6
10.7
1.2
1.2
mmol/l
0.24
40
154
14
13
14.03
13.40
4.6
1.3
—
—
—
0
0
13
12
13.81
12.43
4.5
1.0
9.1
9.3
g/l
0.04
13
12
12
11
13.61
11.45
2.7
1.8
—
—
—
0
0
14
18
10.04
10.65
8.4
4.6
23.0
25.6
mmol/l
1.48
14
18
27
72
6.31
10.62
3.5
5.2
0.8
0.8
mmol/l
0.67
27
66
11
10
13.44
10.49
3.2
1.5
—
—
—
0
0
11
10
13.44
10.49
4.9
1.0
37.9
37.0
g/l
—
11
10
26
70
6.07
10.04
9.8
2.0
10.9
12.5
umol/l
0.67
26
62
12
14
10.64
9.72
2.4
1.2
—
—
—
0
0
24
66
5.61
8.92
10.5
2.0
2.0
2.4
g/l
2.87
24
58
13
9
18.30
8.71
1.5
1.6
—
—
—
0
0
17
35
6.54
8.53
15.6
3.2
5.6
5.6
kpa
0.03
17
35
12
9
16.52
7.81
5.0
1.0
0.0
0.0
g/l
—
12
9
22
66
4.84
7.19
2.6
1.7
—
—
—
0
0
11
18
7.36
6.71
3.0
1.4
—
—
—
0
0
21
64
4.65
6.68
3.3
2.4
30.1
29.5
s
0.23
21
64
12
22
6.67
6.61
4.4
2.4
1.1
1.2
%
0.20
12
22
46
261
5.27
6.09
22.7
11.8
5.2
4.0
e9/l
2.34
46
233
17
47
4.76
6.03
5.8
4.1
—
—
—
0
0
17
49
4.55
5.71
2.6
1.5
—
—
—
0
0
8
5
18.29
5.59
1.3
1.2
—
—
—
0
0
12
26
5.60
5.56
6.8
4.1
112.8
128.5
g/l
1.86
12
26
12
26
5.60
5.56
10.8
8.0
1.3
1.5
mmol/l
0.12
12
26
9
8
13.09
5.51
5.6
1.0
0.0
0.0
g/l
—
9
8
9
8
13.09
5.51
5.6
1.0
0.0
0.0
g/l
—
9
8
17
51
4.35
5.40
2.6
1.5
—
—
—
0
0
14
36
4.85
5.36
1.9
1.7
—
—
—
0
0
9
10
10.45
4.99
1.1
1.9
—
—
—
0
0
40
225
3.72
4.89
8.9
3.3
0.0
0.0
estimate
0.00
14
43
24
101
3.41
4.63
3.0
2.1
3.2
3.3
mg/l
0.09
24
95
14
42
4.11
4.38
2.3
1.6
338.0
409.1
nmol/l
0.66
14
36
39
226
3.39
4.34
11.8
4.5
0.0
0.0
estimate
0.00
14
42
36
199
3.27
4.34
6.0
5.2
—
—
—
0
0
39
227
3.37
4.29
9.1
3.4
0.0
0.0
estimate
0.00
14
40
23
99
3.25
4.22
3.5
3.1
—
—
—
0
0
19
73
3.43
4.17
1.6
1.3
81.1
44.6
iu/ml
0.51
11
22
6
5
13.19
3.85
1.0
1.4
—
—
—
0
0
8
14
6.46
3.48
1.4
1.9
—
—
—
0
0
9
19
5.43
3.40
2.0
1.7
—
—
—
0
0
8
15
6.02
3.32
1.4
1.8
98.6
83.9
%
—
8
15
8
16
5.64
3.18
2.5
2.5
—
—
—
0
0
6
8
8.22
3.13
1.5
1.3
—
—
—
0
0
7
13
5.98
2.97
1.4
1.8
—
—
—
0
0
25
133
2.59
2.94
9.2
3.5
0.0
0.0
estimate
0.00
14
38
9
24
4.26
2.81
4.3
3.1
0.4
0.0
e6/l
—
9
24
7
15
5.17
2.69
1.4
1.8
—
—
—
0
0
26
147
2.43
2.64
6.6
3.4
2.3
2.3
mmol/l
0.82
26
125
5
7
7.69
2.60
1.6
1.4
—
—
—
0
0
6
12
5.45
2.47
1.5
1.7
—
—
—
0
0
5
9
5.97
2.26
1.4
1.1
—
—
—
0
0
6
17
3.82
1.89
1.3
1.3
—
—
—
0
0
29
193
2.04
1.82
9.1
3.3
—
—
—
0
0
6
19
3.41
1.71
8.3
4.8
60.2
55.4
%
—
6
19
5
16
3.32
1.47
2.6
1.7
—
—
—
0
0
13
73
2.02
1.23
4.5
3.7
2.5
2.5
mmol/l
0.21
13
62
23
159
1.76
1.17
3.0
1.9
97.3
97.0
pmol/l
0.00
12
84
35
274
1.74
1.14
4.7
3.0
—
—
—
0
0
11
69
1.74
0.75
2.0
1.7
—
—
—
0
0
0
20
0.00
0.61
0.0
1.5
—
1.4
—
0
15
47
426
1.64
0.61
56.4
13.2
59.5
82.3
ml/min/173m2
4.58
47
344
43
463
0.69
0.44
7.2
4.9
2.4
2.8
mmol/l
1.63
43
434
5
35
1.47
0.40
1.0
2.5
—
—
—
0
0
6
45
1.37
0.35
2.0
2.3
1.9
1.4
%
—
6
40
7
51
1.42
0.33
19.1
7.9
—
—
—
0
0
5
38
1.35
0.24
4.4
21.2
22.9
24.7
mmol/l
—
5
33
5
41
1.24
0.22
1.0
2.6
—
—
—
0
0
12
106
1.17
0.11
1.6
1.9
433.0
482.1
pmol/l
0.29
12
92
14
148
0.93
0.03
4.1
4.6
29.1
20.9
%
—
8
72
32
314
1.04
0.00
5.0
3.1
61.3
48.4
u/l
0.39
32
294
18
181
0.99
0.00
4.1
5.2
2.3
3.8
ug/l
0.39
18
162
5
49
1.02
0.00
2.4
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
4.5
—
17.6
—
0
6
0
5
0.00
0.00
0.0
3.2
—
—
—
0
0
0
5
0.00
0.00
0.0
3.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_CRYOGLOBU and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have D3_CRYOGLOBU.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: D3_CRYOGLOBU – Cryoglobulinemia
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data